Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Lung Cancer Oncologists (EU)(?)

Council Members in this Study Group: 46

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Rossana Berardi, MD
Consultant Medical Oncologist
Università Politecnica delle Marche

Rossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the treatment of solid tumors in particular on gastrointestinal...

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
June 2, 2008
Should we use cetuximab in all NSCLC patients?
By a GLG Expert Contributor
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com

  The FLEX trial, a randomized phase 3 study comparing cisplatin-vinorelbine versus the same regimen plus cetuximab, recently showed that the addition of the monoclonal antibody to chemotherapy significantly prolong survival in chemonaive NSCLC. Several aspects could limit the wide use...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Government/Military Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Physician - Department Chair

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880